文献速递浆细胞疾病

循环肿瘤细胞用于新诊断适合移植的多发性骨髓瘤患者分期

Circulating Tumor Cells for the Staging of Patients With Newly Diagnosed Transplant-Eligible Multiple Myeloma.
PubMed 文献 · J Clin Oncol · 2022-06-06

在374例新诊断多发性骨髓瘤(MM)患者中,于GEM2012MENOS65和GEM2014MAIN试验中检测外周血循环肿瘤细胞(CTC)。92%(344/374)患者可检出CTC,CTC≥0.01%为独立不良预后因素(HR 2.02;95%CI 1.3-3.1;P=.001),CTC不可检出者无论缓解深度如何均预后极佳。

要点

  • 新诊断MM患者外周血CTC检出率达92%(344/374)。
  • CTC≥0.01%是PFS的独立不良预后因素(HR 2.02;95%CI 1.3-3.1;P=.001)。
  • CTC不可检出者无论完全缓解和MRD状态如何,PFS均极佳。

核心结论

  • 外周血CTC评估优于骨髓浆细胞定量。
  • 检出≥0.01% CTC可作为适合移植MM患者新分期系统中的新危险因素。

研究设计与样本

  • 研究纳入GEM2012MENOS65和GEM2014MAIN试验中374例新诊断MM患者,检测外周血CTC。
  • 治疗包括硼替佐米、来那度胺和地塞米松诱导,随后自体移植、巩固和维持治疗。
  • 采用新一代流式细胞术评估诊断时外周血CTC及治疗全程骨髓MRD。

主要发现

  • 92%(344/374)的新诊断MM患者可检出CTC。
  • CTC百分比与骨髓浆细胞百分比的相关性有限。
  • CTC对数百分比升高与无进展生存期(PFS)较差相关。
  • 在多变量PFS分析(纳入国际分期系统、乳酸脱氢酶水平和细胞遗传学)中,CTC cutoff 0.01%显示独立预后价值(HR 2.02;95%CI 1.3-3.1;P=.001)。
  • 四种预后因素联合显著改善风险分层;CTC不可检出者无论完全缓解和MRD状态如何均显示极佳PFS,其他可检出CTC者中仅达到MRD阴性(而非完全缓解)显示PFS统计学显著增加。

关键数值与推荐

  • CTC cutoff 0.01%的独立预后价值:HR 2.02;95%CI 1.3-3.1;P=.001。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Patients with multiple myeloma (MM) may show patchy bone marrow (BM) infiltration and extramedullary disease. Notwithstanding, quantification of plasma cells (PCs) continues to be performed in BM since the clinical translation of circulating tumor cells (CTCs) remains undefined. PATIENTS AND METHODS: CTCs were measured in peripheral blood (PB) of 374 patients with newly diagnosed MM enrolled in the GEM2012MENOS65 and GEM2014MAIN trials. Treatment included bortezomib, lenalidomide, and dexamethasone induction followed by autologous transplant, consolidation, and maintenance. Next-generation flow cytometry was used to evaluate CTCs in PB at diagnosis and measurable residual disease (MRD) in BM throughout treatment. RESULTS: CTCs were detected in 92% (344 of 374) of patients with newly diagnosed MM. The correlation between the percentages of CTCs and BM PCs was modest. Increasing logarithmic percentages of CTCs were associated with inferior progression-free survival (PFS). A cutoff of 0.01% CTCs showed an independent prognostic value (hazard ratio: 2.02; 95% CI, 1.3 to 3.1; P = .001) in multivariable PFS analysis including the International Staging System, lactate dehydrogenase levels, and cytogenetics. The combination of the four prognostic factors significantly improved risk stratification. Outcomes according to the percentage of CTCs and depth of response to treatment showed that patients with undetectable CTCs had exceptional PFS regardless of complete remission and MRD status. In all other cases with detectable CTCs, only achieving MRD negativity (and not complete remission) demonstrated a statistically significant increase in PFS. CONCLUSION: Evaluation of CTCs in PB outperformed quantification of BM PCs. The detection of ≥ 0.01% CTCs could be a new risk factor in novel staging systems for patients with transplant-eligible MM.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Garcés JJ, Cedena MT, Puig N, et al. Circulating Tumor Cells for the Staging of Patients With Newly Diagnosed Transplant-Eligible Multiple Myeloma. J Clin Oncol. 2022. PMID: 35666958. doi:10.1200/JCO.21.01365

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。